Krause, David S |
MedOPT, NCT03468309: Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population |
|
|
| Completed | N/A | 53 | US | Genecept Assay and G-DIG decision tool | Seattle Institute for Biomedical and Clinical Research, Genomind, LLC | Pharmacogenetic Testing | 04/19 | 04/24 | | |
Wood, Amanda E |
MedOPT, NCT03468309: Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population |
|
|
| Completed | N/A | 53 | US | Genecept Assay and G-DIG decision tool | Seattle Institute for Biomedical and Clinical Research, Genomind, LLC | Pharmacogenetic Testing | 04/19 | 04/24 | | |
NCT00512070: Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine |
|
|
| Completed | N/A | 40 | US | olanzapine and melatonin, Olanzapine (Zyprexa) | Seattle Institute for Biomedical and Clinical Research, Eli Lilly and Company | Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Obesity, Metabolic Syndrome | 12/10 | 12/24 | | |
NCT05776719: Efficacy of Virtual Warrior Renew Therapy for Veterans Who Experienced Military Sexual Trauma |
|
|
| Recruiting | N/A | 134 | US | Health & Wellness, Warrior Renew | Seattle Institute for Biomedical and Clinical Research, United States Department of Defense | Military Sexual Trauma (MST), Post Traumatic Stress Disorder | 11/26 | 01/30 | | |